NATIONAL TAIWAN UNIVERSITY (Taiwan, Province of China)
TAIPEI MEDICAL UNIVERSITY (Taiwan, Province of China)
CHOU, Mei-Yin (USA)
Inventor
Lin, Pei-Ying
Huang, Bo-Tsang
Yeh, Chen-Lin
Lai, Wei-Yun
Abstract
The present disclosure relates generally to the field of nucleic acids and more particularly to aptamer(s) conjugating with an therapeutic agent to form an aptamer therapeutics.
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present disclosure discloses a method of generating NK cells resistant to plasmid toxicity, comprising disrupting the activity of cGAS-STING pathway in NK cells. The present disclosure also discloses NK cell or chimeric antigen receptor (CAR)-expressing NK cells and uses thereof.
The present invention relates to a modified cell line wherein one or two ASCT1 and ASCT2 genes are knocked out, and related preparation methods and applications
TAIPEI VETERANS GENERAL HOSPITAL (Taiwan, Province of China)
CHOU, Mei-Yin (USA)
Inventor
Ting, Kuan-Chung
Liu, Kai-Chun
Tsao, Yu
Abstract
A system for detecting otitis media (OM) acoustically is provided. The system comprising a first acoustic receiver, configured to be placed in a patient 's first ear for receiving utterances of the patient; an acoustic sampling circuitry, configured to connect with the first acoustic receiver and io sample the utterances of the patient as first sound signals; a memory, configured to store one or more trained ML or NN (machine learning or neural network) models; and one or more processors, configured, to inference the one or more ML or NN models with the first sound signals as inputs to determine whether the first ear is with OM or not.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
Provided is an engineered bacteriophage particle for gene delivery including an engineered phagemid having a restructure f1 origin of replication, an M13 phage capsid encapsulating the engineered phagemid, and a cell-targeting ligand displayed on the M13 phage capsid. Also provided is a vector system for producing the engineered bacteriophage particle and a method of gene therapy by using the engineered bacteriophage particle.
A high-resolution microelectrode-based neural stimulation system includes at least two stimulating electrodes, a first control module, and a second control module. An overall periphery of the stimulating electrodes defines a stimulation area on the brain tissue. The first control module has a first signal source and at least two first switches. The first signal source provides a first current having a first frequency. The second control module has a second signal source and at least two second switches. The second signal source provides a second current having a second frequency. By controlling the current intensities of any of the two electrodes, stimulation can be selectively provided to a brain tissue on a target site in the stimulation area. The neural stimulation system benefits its user with decreased complexity of electrode installation and reduced setup costs while enabling high-precision stimulation to neurons.
The invention is related to a portable and compact positron emission tomography (PET) system with real-time adaptability, a detector unit contained therein, and an image reconstruction method. The system comprises at least one detector unit, including at least one compact, handheld gamma detector module for front end readout, for processing signals to output serialized data, at least one connecting cable, and a DAQ unit for data acquisition; a computer, interfaced with the at least one detector unit, a robot unit, a user interface and visualization unit, and a perception unit, for processing the received data to generate appropriate responses for each of the units; a perception unit; and a user interface and visualization module, for displaying reconstructed and co-registered images of a patient to be detected in real time.
Disclosed is a novel polynaphthalimide which comprises a repeat unit represented by the following formula (I) wherein naphthalimide is bonded to substructure A, wherein A is a cyano-substituted arylamine moiety. The polynaphthalimide polymer provides an electrode material disposed on an electrode collector, wherein the electrode may be a cathode or an anode, said electrode comprising the disposed polynaphthalimide is utilized in a lithium-ion battery, providing an efficient storage capability of the newly designed triphenylamine-based polynaphthalimides (TPA-PNIs) and exhibiting outstanding electrochemical performance and operation durability.
A method of treating tuberous sclerosis complex (TSC) or epilepsy is provided, including administrating to a subject a compound of formula (I), (II) or (III): (I) (II) (III) or a pharmaceutically acceptable salt thereof, wherein X is halogen. A composition for use in a method of treating TSC or epilepsy, including administering to a subject in need thereof the composition comprising a compound of formula (I), (II) or (III) as shown above is also provided.
Disclosed is an electrolyte solution for a lithium metal battery, comprising: a lithium thiophosphate complex formed by phosphorus pentasulfide and lithium polysulfide. In addition, a lithium metal battery comprising the aforesaid electrolyte solution and a method for preparing the aforesaid electrolyte solution are also disclosed.
H01M 10/0561 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes the electrolyte being constituted of inorganic materials only
Crassocephalum rabensCrassocephalum rabensCrassocephalum rabens plant or extract. The present disclosure also provides an immunogenic composition and a method for enhancing humoral immune response.
The present invention relates to a dengue virus messenger ribonucleic acid (mRNA) vaccine. In particular, the vaccine includes an mRNA encoding a mutant envelop (E) protein of dengue virus at position 8 and/or 101 formulated in lipid nanoparticles. The mRNA vaccine of the present invention is safe and effective, which causes enhanced production of neutralizing antibodies against multiple serotypes of dengue virus and reduced antibody dependent enhancement (ADE) response.
KAOHSIUNG MEDICAL UNIVERSITY (Taiwan, Province of China)
CHOU, Mei-Yin (USA)
Inventor
Chen, Jun-An
Jong, Yuh-Jyh
Abstract
The present invention relates to a MiR34 as a biomarker for spinal muscular atrophy (SMA) and therapeutic/prognosis applications. In particular, the present invention provides a method for treating SMA via modulating MiR34. The present invention also provides a method for prognosis of SMA based on a baseline level of MiR34 in an SMA patient before treatment. The present invention further provides a method for predicting an SMA patient's response to treatment against SMA based on the change of a MiR34 level in the patient before and after the treatment or during the period of the treatment.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61P 43/00 - Drugs for specific purposes, not provided for in groups
15.
METHOD OF TREATING SLEEP DISRUPTIONS AND COMPOSITION FOR USE THEREIN
A method of treating a sleep disruption in a subject in need thereof is provided, including administrating to the subject a compound of formula (I), (II) or (III) or a pharmaceutically acceptable salt thereof, wherein X is halogen. A composition for use in a method of treating a sleep disruption in a subject in need thereof, including administering to the subject in need thereof the composition comprising a compound of formula (I), (II) or (III) as shown above is also provided.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
Disclosed is a method for enhancing the pollen viability of plants. In particular, the method of the present invention comprises treating pollen grains of a flowering plant with an effective amount of the compound Formula (I).
A01G 7/06 - Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
C07C 235/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
The present disclosure relates to a plasma apparatus and a method. The plasma apparatus comprises an inner electrode and an outer electrode. The inner electrode comprises a wall defining a first cavity, and an opening of the first cavity is configured to receive a first gas. The outer electrode surrounds the inner electrode. The inner electrode has a through-hole extending through the wall of the inner electrode, such that the first cavity is in fluid communication with a plasma generation region between the inner electrode and the outer electrode via the through-hole. The inner electrode is rotatable about a first axis of rotation, and the first axis of rotation extends through the first cavity. In particular, some embodiments of the present disclosure relate to a plasma apparatus and a method for cracking a gas.
A method of treating schizophrenia is provided, including administrating to a subject a compound of formula (I), (II) or (III): (I) (II) (III) or a pharmaceutically acceptable salt thereof, wherein X is halogen. A composition for use in a method of treating schizophrenia, including administering to a subject in need thereof the composition comprising a compound of formula (I), (II) or (III) as shown above is also provided.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
19.
ANTI-SCUBE1 ANTIBODY HAVING HIGH INTERNALIZATION CAPACITY IN LEUKEMIA
The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to SCUBE1; wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and/or a light chain variable region, and antibody drug conjugates (ADCs) for killing SCUBE1-expressing cancer cells, as well as methods of treating and/or preventing SCUBE1-expressing cancers.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
20.
METHODS OF DETERMINING CERULOPLASMIN ACTIVITY AND APPLICATIONS THEREOF
Disclosed is a method of determining ceruloplasmin activity using a mass spectrometry technique. The method comprises reacting a biological sample containing ceruloplasmin with a compound of formula I to produce an oxidized product of the compound, measuring a level of the oxidized product by a mass spectrometry technique, and determining a level of ceruloplasmin activity based on the level (amount) of the oxidized product.
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
Disclosed herein are novel lipids, lipid nanoparticles and their uses for the transport of therapeutic agents to a subject, or for the treatment and/or prophylaxis of diseases in the subject.
C07C 219/08 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
Disclosed herein are compounds having adjuvant properties, vaccines including the adjuvant compounds, and their uses in the prophylaxis or therapy for respiratory virus infection.
The present invention provides an atrial fibrillation detection system and method based upon irregularity in inter-pulse duration or interval of a subject's cardiovascular signal. Specifically, the present invention determines existence of atrial fibrillation based upon irregularity in percentage difference in duration or interval of consecutive pulses of a subject's cardiovascular signal. In addition, the present invention applies analysis of flux-interval plots of pulse interval and pulse normalized amplitude to screen out false positives and displays the flux-interval plots to the subject to provide transparency to the subject.
A61B 5/0295 - Measuring blood flow using plethysmography, i.e. measuring the variations in the volume of a body part as modified by the circulation of blood therethrough, e.g. impedance plethysmography
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A61B 5/316 - Modalities, i.e. specific diagnostic methods
A61B 5/364 - Detecting abnormal ECG interval, e.g. extrasystoles or ectopic heartbeats
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
122 is O, –NH or –NRa, in which Ra1-1034 21-101-10)alkyl; and A is aryl, heteroaryl, or heterocyclyl optionally substituted with one or more substituent selected from the group consisting of halo, hydroxyl, amino and phosphate.
The present invention relates to a system and method for predicting blood glucose levels in a non-invasive manner using deduction learning. The deduction learning (DL) model 10 of the present invention predicts blood glucose level 300 based on the relationship or correlation between blood glucose level variation and PPG signal variation. Specifically, the DL model 10 of the present invention comprises a differential cell 100 (DC) configured to calculate predicted blood glucose level BGpred 300 using two PPG signals Si 200b and Si-1 200a, a BG i-l,ref 230 and relationship or correlation between variances of the two PPG signals and variances of the reference blood glucose level 230 and the predicted blood glucose level 300.
A61B 5/1477 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means non-invasive
A61B 5/0245 - Measuring pulse rate or heart rate using sensing means generating electric signals
A61B 5/0295 - Measuring blood flow using plethysmography, i.e. measuring the variations in the volume of a body part as modified by the circulation of blood therethrough, e.g. impedance plethysmography
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
27.
ANTI-SIGLEC-3 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF
Disclosed herein is generally directed to antibodies against the Siglec-3, and pharmaceutical compositions that comprise the antibodies. According to some embodiments of the present disclosure, the present anti-Siglec-3 antibodies may suppress the over activation of Siglec-3, thereby reversing the immunosuppression effects resulted therefrom. As such, the present antibodies may treat diseases associated with the over activation of Siglec-3, such as hepatitis B virus (HBV) infection, neurodegenerative diseases, autoimmune diseases, or cancers. Accordingly, the present disclosure also includes methods for the treatment and/or prophylaxis of the above diseases.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
28.
METHOD OF TREATING SPINAL CORD INJURY AND COMPOSITION FOR USE THEREIN
A method of treating spinal cord injury is provided, including administrating to a subject a compound of formula (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein X is halogen. A composition for use in a method of treating spinal cord injury, including administering to a subject in need thereof the composition comprising a compound of formula (I), (II) or (III) as shown above is also provided.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61P 25/00 - Drugs for disorders of the nervous system
C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
C07D 498/02 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
in vitro or in vivo. in vitro or in vivo. The present disclosure thus provides a covalent peptide/nucleic acid complex useful in such uses. The covalent peptide/nucleic acid complex is formed by the present synthetic peptide and a nucleic acid encoding a target protein linked to each other via covalent bonds formed therebetween. Such covalent peptide/nucleic acid complex is particularly useful for the transformation of antigen presenting cells, such as dendritic cells.
The present disclosure relates to an antibody or antigen-binding fragment thereof that is specific for SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
patents